Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics’ partner, Korea Pharma, has filed a New Drug Application for the iron deficiency treatment Accrufer® in South Korea, with approval expected in 2025. This marks a significant step toward expanding Accrufer®’s global reach, following a successful local pharmacokinetic study confirming its efficacy. Shield Therapeutics stands to receive milestone payments and royalties on Korean sales, while also handling initial manufacturing and supply.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
